Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 11
Submit an article Journal homepage
1,621
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Irene Y. CheungScD, Memorial Sloan Kettering Cancer Center, Department of Pediatrics, 1275 York Avenue, New York, NY, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1427-514X
ORCID Icon,
Brian H. KushnerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
,
Shakeel ModakDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
,
Ellen M. BasuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
,
Stephen S. RobertsDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
&
Nai-Kong V. CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USAORCID Iconhttp://orcid.org/0000-0001-6323-5171
ORCID Icon
Article: e1358331 | Received 02 Jun 2017, Accepted 14 Jul 2017, Published online: 24 Aug 2017

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Michelle E Keyel & C Patrick Reynolds. (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13, pages 1-12.
Read now

Articles from other publishers (18)

Paul T Kennedy, Demetra Zannoupa, Meong Hi Son, Lekh N Dahal & John F Woolley. (2023) Neuroblastoma: an ongoing cold front for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 11:11, pages e007798.
Crossref
Yasuyuki Matsumoto & Tongzhong Ju. (2023) Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. Cancers 15:14, pages 3536.
Crossref
Amalia Varo, Alicia Castañeda, Saray Chamorro, Juan Pablo Muñoz, Maite Gorostegui, Mónica S. Celma, Sandra Lopez, Margarida Simao, Sara Perez-Jaume & Jaume Mora. (2023) Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab. Frontiers in Oncology 13.
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer 413 458 .
Jung-Tung Hung & Alice L. Yu. 2023. Glycosignals in Cancer. Glycosignals in Cancer 215 238 .
Jaume Mora, Godfrey C. Chan, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe & Brian H. Kushner. (2022) Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events. Cancer Reports 6:1.
Crossref
Cristina Bottino, Mariella Della Chiesa, Stefania Sorrentino, Martina Morini, Chiara Vitale, Alessandra Dondero, Annalisa Tondo, Massimo Conte, Alberto Garaventa & Roberta Castriconi. (2022) Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants. Cancers 14:19, pages 4548.
Crossref
Damiano Bartolucci, Luca Montemurro, Salvatore Raieli, Silvia Lampis, Andrea Pession, Patrizia Hrelia & Roberto Tonelli. (2022) MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. Cancers 14:18, pages 4421.
Crossref
Hemant Kumar & Rachna Gupta. (2022) Anti-Disialoganglioside-2 Monoclonal Antibodies as an Emerging Therapeutic Approach in Treatment of High-Risk Neuroblastoma. Current Pharmacology Reports 8:2, pages 112-120.
Crossref
Godfrey Chi-Fung Chan & Carol Matias Chan. (2022) Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules 12:3, pages 358.
Crossref
Nora Berois, Alvaro Pittini & Eduardo Osinaga. (2022) Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers 14:3, pages 645.
Crossref
J. Sebastian Temme, Dorothy L. Butler & Jeffrey C. Gildersleeve. (2021) Anti-glycan antibodies: roles in human disease. Biochemical Journal 478:8, pages 1485-1509.
Crossref
Atif Zafar, Wei Wang, Gang Liu, Xinjie Wang, Wa Xian, Frank McKeon, Jennifer Foster, Jia Zhou & Ruiwen Zhang. (2020) Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews 41:2, pages 961-1021.
Crossref
Piamsiri Sawaisorn, Korakot Atjanasuppat, Usanarat Anurathapan, Somchai Chutipongtanate & Suradej Hongeng. (2020) Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines 8:4, pages 753.
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2020) Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology 38:16, pages 1836-1848.
Crossref
Chi Zhang, Xilin Xiong, Yang Li, Ke Huang, Ling Liu, Xiaomin Peng & Wenjun Weng. (2019) Cytokine‑induced killer cells/natural killer cells combined with anti‑GD2 monoclonal antibody increase cell death rate in neuroblastoma SK‑N‑SH cells. Oncology Letters.
Crossref
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts & Nai-Kong Cheung. (2018) Humanized 3F8 Anti-G D2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma . JAMA Oncology 4:12, pages 1729.
Crossref
Peter Zage. (2018) Novel Therapies for Relapsed and Refractory Neuroblastoma. Children 5:11, pages 148.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.